辉瑞称已取消美塞拉竞购中的部分条件路透特拉华州威明顿11月5日 - 辉瑞PFE.N周三在给特拉华州法官的一封信中说,辉瑞在竞购美塞拉MTSR.O的过程中取消了一些条件,因为它试图克服竞争对手诺和诺德NOVOb.CO对这家肥胖症药物开发商的100亿美元竞购。
辉瑞将在周三举行的听证会上请求特拉华州法官阻止美特斯邦威终止双方的合并协议,支持诺和诺德的出价。辉瑞表示,它取消了对美特斯邦威直接销售股票和公开声明的条件。
(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)
At the request of the copyright holder, you need to log in to view this content
LOGIN / SIGN UPDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.